Recent advances in the management of viral infections

  • John R. Wingard
Part of the Cancer Treatment and Research book series (CTAR)


The immunocompromised cancer patient is vulnerable to a wide spectrum of viral pathogens (Table 1). There has been increasing recognition of viruses as clinically important pathogens in cancer patients during the past decade. In part this is attributable to improved diagnostic techniques to better recognize viral pathogens as causes of illnesses not earlier recognized to be virally caused. In part this is also due to the increasing dose intensity of cytoreductive regimens used to control cancer, the increasing use of bone marrow transplantation (BMT) in the treatment of neoplastic diseases, and improvements in supportive care that permit patients to survive bacterial and fungal infections that in the past might have led to death before viral illness became manifest. Thus, there are greater numbers of highly immunosuppressed patients with severe compromise in cell-mediated immunity, the major host defense against most viral pathogens.


Bone Marrow Transplant Respiratory Syncytial Virus Immune Globulin Allogeneic Bone Marrow Hemorrhagic Cystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pruneda RC, Almanza I. Centrifugation-shell vial technique for rapid detection of herpes simplex virus cytopathic effect in vitro cells. J Clin Microbiol 1987;25:423.PubMedGoogle Scholar
  2. 2.
    Schmidt NJ, Dennis J, Devlin V, Callo D, Mills J. Comparison of direct immunofluorescence and direct immunoperoxidase procedures for detection of herpes simplex virus antigen in lesion specimens. J Clin Microbiol 1983;18:445–448.PubMedGoogle Scholar
  3. 3.
    Gonik B, Seibel M, Berkowitz A, Woodin MB, Mills K. Comparison of two enzyme-linked immunosorbent assays for detection of herpes simplex virus antigen. J Clin Microbiol 1991;29:436–438.PubMedGoogle Scholar
  4. 4.
    Nahass GT, Goldstein BA, Zhu WY, Serfing NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnosis methods in detection of herpes simplex and varicella-zoster infection. JAMA 1992;268:2541–44.PubMedGoogle Scholar
  5. 5.
    Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for the treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73A:229.Google Scholar
  6. 6.
    Mitchell CD, Gentry SR, Boen JR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981;2:1389.Google Scholar
  7. 7.
    Shepp DH, Newton BA, Dandliker PS, et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. Ann Intern Med 1985;102:783.PubMedGoogle Scholar
  8. 8.
    Wade JC, Newton B, McLaren C, et al. Treatment of mucocutaneous herpes simplex virus infection after marrow transplantation with intravenous acyclovir: A double blind trial. Ann Intern Med 1982;96:265.PubMedGoogle Scholar
  9. 9.
    Selby PJ, Jameson B, Watson JG, et al. Parenteral acyclovir therapy for herpes virus infections in man. Lancet 1980;2:1267.Google Scholar
  10. 10.
    Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med 1981;305:63.PubMedGoogle Scholar
  11. 11.
    Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients: A randomized, double-blind placebo controlled study. Ann Intern Med 1983;99:773.PubMedGoogle Scholar
  12. 12.
    Anderson H, Scarfee JH, Sutton RNP, Hickmott E, Brigden D, Burke C, Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind placebo controlled trial. Br J Cancer 1984;50:45–49.PubMedGoogle Scholar
  13. 13.
    Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir prophylaxis of herpes simplex virus infection after marrow transplant. Ann Intern Med 1984;100:823.PubMedGoogle Scholar
  14. 14.
    Wade JC, Newton B, Flournoy N, et al. Acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984;99:773–776.Google Scholar
  15. 15.
    Saral R. Management of acute viral infections. NCI Monogr 1990;9:107–110.PubMedGoogle Scholar
  16. 16.
    Wingard JR. Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphom 1993;11:115–125.Google Scholar
  17. 17.
    Ambinder RF, Burns WH, Lietman PS, et al. Prophylaxis: A strategy to minimize antiviral resistance. Lancet 1984;1:1154–1155.PubMedGoogle Scholar
  18. 18.
    Angelopulos A, Gore S, Braine H, Humphrey R, Miller C, Rossiter C, Burke PJ. Successful intravenous acyclovir (ACV) prophylaxis against Herpes Simplex Virus (HSV) infection/ reactivation during intensive chemotherapy of leukemia. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Franciso, CA, September 17–20, 1995, abstract # H143.Google Scholar
  19. 19.
    Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983;148:1077–1082.PubMedGoogle Scholar
  20. 20.
    Burns WH, Santos GW, Saral R, et al. Isolation and characterizations of resistant herpes simplex virus after acyclovir therapy. Lancet 1982;2:421.Google Scholar
  21. 21.
    McLaren C, Chen MS, Ghazzouli I, Saral R, Burns WH. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agent Chemother 1985;28:740–744.Google Scholar
  22. 22.
    Safrin S, Assakeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant muco-cutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data. J Infect Dis 1990;161:1078.PubMedGoogle Scholar
  23. 23.
    Safrin S, Crumpacker C, Chatis, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551–555.PubMedGoogle Scholar
  24. 24.
    Shepp DH, Dandliker PS, deMiranda P, et al. Activity of 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368.PubMedGoogle Scholar
  25. 25.
    Bratanow NC, Ash RC, Turner PA. Successful treatment of serious cytomegalovirus (CMV) disease with 9(1, 3-dihydroxy-2-propoxymethyl)guanine (ganciclovir), DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients (abstract no. 254). Exp Hematol 1987;15:541.Google Scholar
  26. 26.
    Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777–782.PubMedGoogle Scholar
  27. 27.
    Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783–788.PubMedGoogle Scholar
  28. 28.
    Schmidt GM, Kovacs A, Zaia JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988;46:905–907.PubMedGoogle Scholar
  29. 29.
    Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173–178.PubMedGoogle Scholar
  30. 30.
    Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993;118:179–184.PubMedGoogle Scholar
  31. 31.
    Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N Engl J Med 1991;324:1005–1011.PubMedGoogle Scholar
  32. 32.
    Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med 1991;325:1601–1607.PubMedGoogle Scholar
  33. 33.
    Leland DS, Hansing RL, French ML. Clinical experiences with cytomegalovirus isolation using conventional cell cultures and early antigen detection in centrifugation-enhanced shell vial cultures. J Clin Microbiol 1989;27:1159–1162.PubMedGoogle Scholar
  34. 34.
    Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1985;21:217.PubMedGoogle Scholar
  35. 35.
    Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992;80:1358–1364.PubMedGoogle Scholar
  36. 36.
    van der Bij W, Torensma R, van Son WJ, et al. Rapid immunodiagnosis of active cytomega-lovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988;25:179–188.PubMedGoogle Scholar
  37. 37.
    Jiwa NM, van de Rijke FM, Mulder A, et al. An improved immunocytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry 1989;91:345–349.PubMedGoogle Scholar
  38. 38.
    Spector SA, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992;30:2359–2365.PubMedGoogle Scholar
  39. 39.
    Brytting M, Xu W, Wahren B, et al. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992;30:1937–1941.PubMedGoogle Scholar
  40. 40.
    Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991;77:1104–1110.PubMedGoogle Scholar
  41. 41.
    Nolte FS, Emmens RK, Thurmond C, Mitchell PS, Pascuzzi C, Devine SM, Saral R, Wingard JR. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995;33:1263–1266.PubMedGoogle Scholar
  42. 42.
    Landry ML, Fergussen D. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol 1993;31:2851–2856.PubMedGoogle Scholar
  43. 43.
    Schmidt CA, Oettle H, Wilborn F, Jessen J, Timm H, Schwerdtfeger R, Oertal J, Siegert W. Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant 1994;83:71–75.Google Scholar
  44. 44.
    Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994;19:287–98.PubMedGoogle Scholar
  45. 45.
    Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994;83:2392–2398.PubMedGoogle Scholar
  46. 46.
    Devine SM, Wingard JR. Viral infections in severely immunocompromised cancer patients. Support Care Cancer 1994, 2:355–368.PubMedGoogle Scholar
  47. 47.
    Singhal S, Mehta J, Powles R, Treleaven J, Horton C, Carrington D, Tryhon Y, Jameson B. Three weeks of ganciclovir for cytomegalovirus after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:777–781.PubMedGoogle Scholar
  48. 48.
    Polis MA, Masur H. Promising new treatments for cytomegalovirus retinitis. JAMA 1995;273:1457–1459.PubMedGoogle Scholar
  49. 49.
    Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, Shadman A. Buhles W (for the Syntex Cooperative Oral Ganciclovir Study Group). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615–620.PubMedGoogle Scholar
  50. 50.
    Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716–719.PubMedGoogle Scholar
  51. 51.
    Chou S, Guentzel S, Michels R, Miner RC, Drew WL. Frequency of UL97 phospho-transferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239–242.PubMedGoogle Scholar
  52. 52.
    Razis E, Cook P, Mittelman A, Ahmed T. Treatment of ganciclovir resistant cytomegalovirus with foscarnet: A report of two cases occurring after bone marrow transplantation. Leuk Lymphom 1994;12:477–480.Google Scholar
  53. 53.
    Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70–75.PubMedGoogle Scholar
  54. 54.
    Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749–753.PubMedGoogle Scholar
  55. 55.
    Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246–250.PubMedGoogle Scholar
  56. 56.
    Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas D, Meyers JD. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006–1010.PubMedGoogle Scholar
  57. 57.
    Mackinnon S, Burnett AK, Crawford RJ, Cameron S, Leask BGS, Sommerville RG. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988;41:948–950.PubMedGoogle Scholar
  58. 58.
    Miller W, McCullough J, Balfour HH, et al. Prevention of CMV infection by blood products: A randomized trial (abstract K128). J Cell Biochem 1988;12(Suppl. C):93.Google Scholar
  59. 59.
    De Witte T, Schattenbereg A, Van Dijk BA, Galama J, Olthuis H, Van Der Meer JWW, Kunst VAJM. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990;50:964–968.Google Scholar
  60. 60.
    Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reducted cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;85:3598–3603.Google Scholar
  61. 61.
    Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987;106:12–18.PubMedGoogle Scholar
  62. 62.
    Bass EB, Powe NR, Goodman SN, et al. Efficacy of intravenous immune globulin in preventing complications of bone marrow transplantation: A meta analysis. Bone Marrow Transplant 1993;12:273–282.PubMedGoogle Scholar
  63. 63.
    Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 1994;13:163–167.PubMedGoogle Scholar
  64. 64.
    Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991;164:483–487.PubMedGoogle Scholar
  65. 65.
    Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: A critical review. Bone Marrow Transplant 1994;13:499–510.PubMedGoogle Scholar
  66. 66.
    Sullivan KM, Kopecky KJ. Jocum J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990:323:705–712.PubMedGoogle Scholar
  67. 67.
    Schiller GJ, Nimer SD, Gajewski JL, Golde D. Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant 1991;7:489–491.PubMedGoogle Scholar
  68. 68.
    Balfour HH Jr, Bean B, Laskin OL, et al. and the Burroughs Wellcome Collaborative Acyclovir Study Group. Acyclovir halts progression of herpes zoster in immuno-compromised patients. N Engl J Med 1983;308:1448–1453.PubMedGoogle Scholar
  69. 69.
    Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984:37:571.PubMedGoogle Scholar
  70. 70.
    Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986;314:208–212.PubMedGoogle Scholar
  71. 71.
    McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J 1986;293:1529–1532.Google Scholar
  72. 72.
    Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G for the Nordic Bone Marrow Transplant Group. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989:4:613–615.PubMedGoogle Scholar
  73. 73.
    Boivin G, Edleman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994:170:68–75.PubMedGoogle Scholar
  74. 74.
    Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991;115:19–21.PubMedGoogle Scholar
  75. 75.
    Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983;147:737.PubMedGoogle Scholar
  76. 76.
    Gershon AA. Live attenuated varicella vaccine: Perspective. J Infect Dis 1985;152:859.PubMedGoogle Scholar
  77. 77.
    Gershon AA, Steinberg SP, and the Varicella Vaccine Collaborative Study Group of the NIAID. Persistence of immunity of varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989;320:892.PubMedGoogle Scholar
  78. 78.
    Gershon AA, Steinberg SP, and the National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine: Protection in healthy adults compared with leukemic children. J Infect Dis 1990;161:661.PubMedGoogle Scholar
  79. 79.
    Lawrence R, Gershon AA, Holzman R, et al. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 1988;318:543.PubMedGoogle Scholar
  80. 80.
    Ballerini P, Gaidano G, Inghirami G, Gong JZ, Saglio G, Knowles DM, Dalla-Favera R. Multiple genetic alterations in AIDS-associated lymphomas. Blood 1991;78:327.Google Scholar
  81. 81.
    Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552–565.PubMedGoogle Scholar
  82. 82.
    Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, Ash RC. Interstitial pneumonitis associated with human herpesvirus six (HHV-6) infection in marrow transplant patients. Lancet 1991;338:147.PubMedGoogle Scholar
  83. 83.
    Cone RW, Hackman RC, Huang MW, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993;329: 156.PubMedGoogle Scholar
  84. 84.
    Drobyski WR, Knox KK, Majewski D, Carrigan DR. Fatal encephalitis due to variant B human herpesvirus 6 infection in a bone marrow transplant recipient. N Engl J Med 1994;330:1356.PubMedGoogle Scholar
  85. 85.
    Drobyski WR, Dunne WM, Burd EM. Human herpesvirus 6 (HHV-6) infection in allogeneic bone marrow transplant recipients: I. Evidence for a marrow suppressive role for HHV-6 in vivo. J Infect Dis 1993:167:735.PubMedGoogle Scholar
  86. 86.
    Carrigan DR, Knox KK. Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood 1994;84:3307–3310.PubMedGoogle Scholar
  87. 87.
    Burns WH, Sandford GR. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 1990;162:634–637.PubMedGoogle Scholar
  88. 88.
    Quinnan GV Jr., Kirmani N, Rook AH, et al. Cytotoxic cells in cytomegalovirus infections. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1982;307:7.PubMedGoogle Scholar
  89. 89.
    Reusser P, Riddel SR, Meyers SD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373–1380.PubMedGoogle Scholar
  90. 90.
    Quinnan GV Jr, Burns WH, Kirmani N, et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in infections. Rev Infect Dis 1984;6:156–163.PubMedGoogle Scholar
  91. 91.
    Riddel SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8 cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994;14:S78–S84.Google Scholar
  92. 92.
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992;257:238.PubMedGoogle Scholar
  93. 93.
    Riddell SR, Reusser P, Greenberg PD. Cytotoxic T-cells specific for cytomegalovirus: A potential therapy for immunocompromised hosts. Rev Infect Dis 1991;13:966.Google Scholar
  94. 94.
    Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transplant by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038–1044.PubMedGoogle Scholar
  95. 95.
    Papadopopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185–1191.Google Scholar
  96. 96.
    Davis GL, Baiart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–1506.PubMedGoogle Scholar
  97. 97.
    Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506–1510.PubMedGoogle Scholar
  98. 98.
    Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995;332:1509–1511.PubMedGoogle Scholar
  99. 99.
    Greenberg HB, Pollard RB, Lutwixk LI, et al. Effect of human leukocyte interferon on hepatitis B virus infection on patients with chronic active hepatitis. N Engl J Med 1976;295:517.PubMedGoogle Scholar
  100. 100.
    Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991;77:195–200.PubMedGoogle Scholar
  101. 101.
    Locasciulli A, Bacigalupo A, VanLint MT, Cavalletto D, Pontisso P, Testa M, Masera G, Shulman HM, Portmann B, Alberti A. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;16:407–411.PubMedGoogle Scholar
  102. 102.
    Fujii Y, Kaku K, Tanaka M, et al. Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;13:523–526.PubMedGoogle Scholar
  103. 103.
    Shuhart MC, Myerson D, Childs BH. Marrow transplantation from hepatitis C virus seropositive donors: Transmission rate and clinical course. Blood 1994;84:3229–3235.PubMedGoogle Scholar
  104. 104.
    Frickhofen N, Wisneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83:1998–2004.PubMedGoogle Scholar
  105. 105.
    Ljungman P, Johansson N, Aschan J, Glaumann H, Lönnqvist B, Ringdén O, Sparrelid E, Sönnerborg J, Winiarski J, Gahrton G. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995;86:1614–1618, 1995.PubMedGoogle Scholar
  106. 106.
    Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993;104:1818–1821.PubMedGoogle Scholar
  107. 107.
    Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994;169:775–781.PubMedGoogle Scholar
  108. 108.
    Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11:1–5.PubMedGoogle Scholar
  109. 109.
    Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HC1 and rimantidine HC1 in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 1969;281:579.PubMedGoogle Scholar
  110. 110.
    Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine 1989;68:269–281.PubMedGoogle Scholar
  111. 111.
    Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24–29.PubMedGoogle Scholar
  112. 112.
    Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JL. Elting LS, Bodey GP. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393–399.PubMedGoogle Scholar
  113. 113.
    Englund JA, Anderson LJ, Rhame FS. Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol 1991;29:115–119.PubMedGoogle Scholar
  114. 114.
    Whimbey E, Elting LS, Cough RB, Lo W, Williams L, Champlin RE, Bodey GP. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994;13:437–440.PubMedGoogle Scholar
  115. 115.
    Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986;315:230–234.PubMedGoogle Scholar
  116. 116.
    Russell SJ, Vowels MR. Vale T. Haemorrhagic cystitis in paediatric bone marrow transplant patients: An association with infective agents, GVHD and prior cyclophosphamide. Bone Marrow Transplant 1994;13:533–539.PubMedGoogle Scholar
  117. 117.
    Azzi A, Fanci R, Bosi A, et al. Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: An approach to assess the relationship between BK viruria and hemorrhagic cystitis. Bone Marrow Transplant 1994;14:235–240.PubMedGoogle Scholar
  118. 118.
    Schneider EM, Dörries. High frequency of polyomavirus infection in lymphoid cell preparations after allogeneic bone marrow transplantation. Transplant Pro 1983;25:1271–1273.Google Scholar
  119. 119.
    Drummond JE, Shah KV, Saral R, Santos GW, Donnenberg AD. BK virus specific humoral and cell mediated immunity in allogeneic bone marrow transplant (BMT) recipients. J Med Virol 1987;23:331–344.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • John R. Wingard

There are no affiliations available

Personalised recommendations